New Delhi, Jan. 29 -- Shares of Sudarshan Pharma closed Thursday's session, January 29, with nearly a 4% surge at Rs.20.25 apiece as investors appeared to be pleased with the company's performance in the December quarter.

The company during market hours announced its Q3 results, along with 9MFY26 performance. It reported a revenue of Rs.168 crore in Q3FY26, up from Rs.115 crore in Q3FY25, marking a 37% YoY growth.

For the nine months ended December 31, 2025 (9MFY26), revenue rose to Rs.467.69 crore from Rs.340.93 crore in 9MFY25, reflecting a strong 37% increase.

The company's EBITDA (profit before finance cost, depreciation, and tax) for Q3FY26 stood at approximately Rs.10.87 crore, compared to Rs.7.97 crore in Q3FY25.

For 9MFY26, EB...